Navigating Your Path to Weight Loss: Understanding What is the Normal Dose of Wegovy

Last reviewed: July 8, 2026

Last updated: July 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide, the active ingredient in Wegovy, typically begins at 0.25 mg weekly and advances over 16–20 weeks to a maintenance dose between 1.7 and 2.4 mg weekly. However, this standard protocol does not account for individual differences in GLP-1 receptor sensitivity, metabolic capacity, or genetic predispositions that influence how your body responds to treatment.

How Semaglutide Dosing Works in Clinical Practice

Semaglutide is a GLP-1 receptor agonist that signals your brain's appetite control centers and slows gastric emptying. The medication is administered as a once-weekly injection, and healthcare providers follow a gradual titration schedule to minimize nausea and allow your body to adapt. Most patients progress through four escalating doses—0.25 mg, 0.5 mg, 1.0 mg, and finally 1.7 or 2.4 mg—each held for one month before advancing.

The rationale behind slow titration is twofold: first, it allows your gastrointestinal system to acclimate to the medication's effects on appetite and stomach function; second, it identifies your therapeutic threshold—the dose at which you experience meaningful weight loss without intolerable side effects. Clinical trials have shown that approximately 65% of patients on semaglutide achieve at least a 10% reduction in body weight, with some reaching 15% or higher.

Why Standard Dosing May Not Match Your Metabolic Needs

Pharmaceutical companies design standard dosing schedules to work for the broadest population, not for individual biochemistry. Your genetic makeup influences how efficiently your GLP-1 receptors function, how your pancreas releases insulin in response to the drug, and how your liver processes the medication. Two patients following identical dose schedules may experience vastly different results because their genetic architecture differs.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR and FTO — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Wegovy or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Starting Low and Progressing at Your Own Pace

Many patients benefit from slower titration than the standard schedule suggests. Beginning at 0.25 mg and remaining at that dose for 2–3 weeks allows early detection of individual tolerability. Some patients experience minimal nausea and achieve meaningful appetite suppression at lower doses, while others may require a faster progression to reach therapeutic effect. Neither outcome is wrong—it reflects your unique physiology.

PlexusDx compounded semaglutide injections are available in flexible dosing increments, allowing your provider to adjust your progression independently of rigid pharmaceutical schedules. Your dose may need to go up. Your price won't—PlexusDx charges a flat monthly rate of $189 to start, removing the financial pressure to advance your dose quickly. This pricing model aligns treatment decisions with your biology, not your wallet.

Personalization Beyond Dose: The Role of Genetic Testing

Understanding your genetic predispositions transforms semaglutide therapy from a trial-and-error process into a precision strategy. The PlexusDx Precision Peptide Genetic Test identifies your personal peptide-pathway profile—not just how you metabolize drugs, but how your appetite-control genes respond to GLP-1 signals. Key genetic variants like MC4R rs17782313 (linked to leptin sensitivity) and GIPR rs1800437 (linked to glucose-dependent insulin secretion) reveal whether your body is primed to respond robustly to semaglutide or whether you may benefit from combination therapy or alternative peptides.

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Comparing Compounded Semaglutide to Brand-Name Wegovy

Wegovy and compounded semaglutide contain the same active ingredient and work through identical mechanisms. The primary differences are cost, flexibility, and accessibility. Brand-name Wegovy requires insurance coverage or out-of-pocket payment that often exceeds $1,000 monthly, whereas PlexusDx compounded semaglutide from licensed 503A compounding pharmacies is $189 monthly month-to-month, or from $149/mo on the 6-month plan. Both are equally safe when sourced from legitimate providers.

Compounded semaglutide through PlexusDx is HSA/FSA eligible, requires no membership fee, and is available in all 50 states. Because compounding pharmacies prepare medications in custom batches rather than pre-filled pens, your provider has greater flexibility in adjusting your dose without waste. This flexibility, combined with transparent flat pricing, positions PlexusDx as a patient-centered alternative for those seeking both affordability and personalization.

Managing Side Effects During Dose Escalation

Nausea is the most common side effect during semaglutide titration, typically occurring in the first 2–3 weeks at each new dose level before subsiding. Constipation and decreased appetite (desired in therapeutic doses, but sometimes uncomfortably intense) also appear frequently. These effects are dose-dependent and usually reversible—they signal that the medication is engaging your GLP-1 pathways, not that treatment is failing.

Strategies to minimize discomfort include eating smaller, lower-fat meals; staying hydrated; and increasing fiber intake gradually. If nausea persists beyond three weeks at a stable dose, discuss pausing advancement with your provider rather than abandoning treatment. Some patients find that staying at 1.0 or 1.4 mg semaglutide yields meaningful weight loss without progression to higher doses—your therapy target is the dose that balances efficacy and tolerability for your life, not the highest dose possible.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

What is the typical starting dose of semaglutide for weight loss?

Semaglutide treatment typically begins at 0.25 mg injected weekly, with progression to 0.5 mg, 1.0 mg, and maintenance doses of 1.7–2.4 mg over 16–20 weeks. PlexusDx providers can modify this schedule based on your individual response, tolerability, and genetic profile—your dose may advance slower or stabilize at a lower level if that's what your body needs.

Do all patients need to reach the 2.4 mg maintenance dose?

No. Clinical trials show that meaningful weight loss occurs at multiple dose levels; some patients achieve 10–15% weight reduction at 1.0 or 1.4 mg, while others require higher doses. Your optimal dose is the lowest one that delivers the results you want with side effects you can tolerate. PlexusDx's flat-rate pricing structure ($189/mo to start) means you're never financially pushed toward higher doses.

How does PlexusDx pricing work if I need a higher dose?

PlexusDx charges a flat monthly rate for compounded semaglutide injections at $189/mo month-to-month, or from $149/mo on the 6-month plan, with no additional fees as your dose increases across commitment tiers. This pricing model ensures your treatment decisions stay focused on your health, not your budget. The medication is available in all 50 states and is HSA/FSA eligible.

Is compounded semaglutide as safe and effective as Wegovy?

Yes. PlexusDx compounded semaglutide is prepared by licensed 503A compounding pharmacies and contains the identical active ingredient as Wegovy. The main advantages are lower cost, greater dosing flexibility, and wider accessibility. Both require medical supervision and carry the same safety profile when properly administered.

How does the Precision Peptide Genetic Test relate to my GLP-1 pathway?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Wegovy For Weight Loss 2
• Wegovy Weight Loss Pills
• Wegovy Vs Zepbound Weight Loss
• Wegovy Weight Loss

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.